Hypertension: Clinical Evidence for Leech Therapy

Uncontrolled Russian-language reports that are not independently verifiable; no randomized controlled trial exists

Last Updated: May 26, 2026Reviewed by: Andrei Dokukin, MDTier C — Investigational / researchGRADE: Very Low

Investigational cardiovascular evidenceMechanism rationale

Investigational / Research Priority

Leech therapy for hypertension is an investigational application of an FDA 510(k)-cleared medical device. No randomized controlled trials have been conducted for this indication. The available evidence consists of controlled observational studies and case series conducted in Russia and other former Soviet countries. This application is classified as Tier C (Investigational) under the ASH evidence classification system.

Investigational Application

Hypertension is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

Evidence Profile

No RCTs exist for hypertension. The claims that previously appeared here rested on uncontrolled Russian-language reports that are not independently verifiable; no randomized controlled trial exists. Any suggestion of efficacy or of clinical or pharmaco-economic benefit would require testing in randomized trials that have not been conducted.

Part I: Epidemiology and Disease Burden

Hypertension is the single largest modifiable risk factor for cardiovascular mortality worldwide. Despite a full pharmacological arsenal, blood pressure control rates remain suboptimal, creating clinical demand for adjunctive interventions.

1.28 billion

Adults with hypertension worldwide (WHO 2023)

119.9 million

US adults with hypertension (48.1% prevalence; NHANES 2017–March 2020)

~50%

Of treated patients fail to achieve target BP (<130/80 mmHg)

$131 billion

Annual US direct healthcare cost attributable to hypertension

Therapeutic Gap: Resistant and Difficult-to-Treat Hypertension

Approximately 14% of treated hypertensive patients (pooled prevalence 13.7%, 95% CI 11.2–16.2%) meet criteria for resistant hypertension (BP above target despite 3+ medications including a diuretic). These populations represent the most compelling clinical niche for adjunctive leech therapy investigation:

Pharmacological limitations: Each additional antihypertensive agent adds incremental toxicity (electrolyte disturbance, orthostatic hypotension, metabolic effects) with diminishing efficacy returns.
Non-pharmacological gaps: Lifestyle modification (DASH diet, exercise, weight loss) is effective but adherence is poor. Renal denervation has shown mixed results.
Leech therapy rationale: The multi-target mechanism (volume reduction + vasodilation + microcirculatory improvement + autonomic reflex) addresses multiple pathogenic pathways simultaneously, potentially complementing pharmacotherapy.

Part II: Antihypertensive Mechanism of Action

GRADE Evidence Level: Very Low

Case reports, case series, or expert opinion only

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

The antihypertensive effect of leech therapy is attributed to four distinct but synergistic mechanisms, each targeting a different component of blood pressure regulation. This multi-target pharmacology distinguishes leech therapy from single-mechanism antihypertensive drugs and may explain the observed magnitude and duration of effect.

1. Controlled Bloodletting (Volume Reduction)

Each leech extracts 5–15 mL during feeding, followed by 20–50 mL of post-detachment bleeding (4–24 hours). With 4–8 leeches per session, total blood loss is 100–520 mL. This acute volume reduction decreases preload, cardiac output, and systemic blood pressure. The mechanism is analogous to therapeutic phlebotomy, which has demonstrated a blood-pressure-lowering effect in one randomized trial in metabolic syndrome (Houschyar 2012; attributed to iron reduction).

Study	n	SBP Reduction	Improvement Rate	Duration
Uncontrolled Russian-language report (not independently verifiable)	94 + 20	15–25 mmHg	75% (vs 35% control)	Not reported
Uncontrolled Russian-language report (not independently verifiable)	83	10–20 mmHg	82%	Not reported
Baskova 2004	42	Not specified	73.8%	Up to 35 years follow-up
Uncontrolled Russian-language report (not independently verifiable)	46	Not specified	100%	Up to 4 months
Uncontrolled report (unverifiable)	530 (cardiac)	Significant (co-outcome)	60–68%	Not reported

Key Finding: Duration of Effect

A sustained antihypertensive effect outlasting the treatment course has been described only in uncontrolled Russian-language reports that are not independently verifiable. Such a sustained effect could not be explained by the acute volume-reduction mechanism alone (circulating blood volume is restored by autodilution within hours: six to eight hours after a 480 mL donation in healthy volunteers), and would instead suggest vascular remodeling, persistent improvement in endothelial function, or resetting of the baroreflex set-point. Any such duration profile would require confirmation in controlled trials before it could be relied upon.

Subgroup Observations

Russian-language clinical reports have suggested that response to leech therapy in hypertension may vary by patient age, hypertension type, and disease stage, but these observations come from uncontrolled sources and the specific response rates cannot be independently verified.

Part IV: Treatment Protocol

The following protocol synthesizes approaches from the five clinical studies and the Michalsen, Roth, and Dobos (2007) hospital protocol from Essen-Mitte, Germany. All protocols place primary emphasis on the mastoid process as the application site.

Parameter	Primary Protocol (Mastoid)	Secondary Sites (Adjunctive)
Application site	Mastoid process, 1 cm posterior and inferior to the ear, bilaterally	Left precordial zone (3rd–5th intercostal spaces); right hepatic region; sacral area (lumbosacral zone)
Leeches per session	4–8 (2–4 per mastoid)	2–4 to secondary site (if used)
Session frequency	Every 3–4 days	Same schedule
Total sessions	3–5 (standard course)	Included in total
Feed method	Full feed (spontaneous detachment, 20–45 min)	Full feed
Blood pressure monitoring	Pre-session, 1-hour post, next-day; then weekly during course	Same
Total leeches per course	15–35	—
Expected onset	Reported within about 30–60 minutes or more after application (uncontrolled reports); a transient BP rise was also reported in some patients	—
Duration of effect	Long-term data not available	—

Critical Safety Considerations

Antihypertensive medication must NOT be discontinued during or after leech therapy unless directed by the prescribing physician based on documented, sustained blood pressure improvement. Leech therapy is investigated as an adjunct to pharmacotherapy, not a replacement. Patients with concurrent anticoagulation require careful risk-benefit assessment: the additive anticoagulant effect of hirudin combined with antihypertensives that affect hemostasis (e.g., ACE inhibitors reducing aldosterone) may increase bleeding duration.

Application Site Rationale

The choice of application site in hypertension treatment follows dermatomal and autonomic neuroanatomy:

Site	Dermatome	Autonomic Connection	Clinical Rationale
Mastoid process	C2–C3	Vagal innervation, carotid sinus baroreceptor zone	Primary site: activates baroreflex, promotes parasympathetic tone
Precordial zone	T1–T5	Cardiac sympathetic innervation	Concurrent coronary artery disease; cardiac symptom relief
Right hepatic region	T7–T9	Hepatic congestion relief	Portal hypertension component; right heart failure
Lumbosacral zone	L1–S2	Renal sympathetic innervation	Renal hypertension; renin-angiotensin modulation

Part V: Drug Interactions in Hypertensive Patients

Hypertensive patients are frequently polypharmacy patients. The following drug interactions are documented or theoretically significant based on SGS pharmacology:

Drug Class	Interaction Mechanism	Risk	Recommendation
ACE inhibitors / ARBs	Additive hypotension; reduced aldosterone may increase bleeding	Moderate	Monitor BP closely; patient should be supine during treatment
Beta-blockers	Additive bradycardia (vagal stimulation from mastoid application)	Moderate	Monitor heart rate; caution with high-dose beta-blockade
Calcium channel blockers	Additive vasodilation; peripheral edema may increase	Low–Moderate	Generally well tolerated; monitor for orthostatic symptoms
Diuretics	Volume depletion + leech bloodletting = excessive volume loss	Moderate	Ensure adequate hydration; monitor for orthostatic hypotension
Warfarin / DOACs	Synergistic anticoagulation with hirudin in SGS	High	Relative contraindication; INR must be <3.0 if warfarin; assess risk-benefit
Antiplatelet agents (aspirin, clopidogrel)	Additive antiplatelet effect with calin, decorsin, apyrase	Moderate–High	Do not discontinue cardiovascular prophylaxis; expect longer bleeding
Nitrates	Additive vasodilation and hypotension	Moderate	Withhold sublingual nitrates on treatment day unless anginal symptoms
Statins	No known interaction with SGS components	Low	Continue unchanged

Part VI: Safety Profile

GRADE Evidence Level: Very Low

Case reports, case series, or expert opinion only

Safety data from the five hypertension studies are consistent with the general safety profile of leech therapy. No serious adverse events (hospitalization, organ damage, death) have been reported in any hypertension study. The primary hypertension-specific concern is additive hypotension in patients already on antihypertensive medication.

Adverse Event	Incidence	Management
Orthostatic hypotension	8–12% (estimated)	Supine position during treatment and 30 min after; oral hydration
Local pruritus (mastoid area)	25–30%	Topical antihistamine; cooling compresses; typically resolves without medical intervention
Prolonged bleeding from bite sites	Not established (no controlled data in hypertension)	Pressure dressing if >24 hours; check medication list
Vasovagal episode	3–8%	Supine positioning; may be more common in treatment-naïve patients
Visible bite scars (behind ear)	~100%	Typically concealed by hair; usually leaves a scar, so counsel in consent

Contraindications Specific to Hypertension

Absolute: Hypertensive emergency (SBP >180 or DBP >120 with acute end-organ damage); concurrent full-dose anticoagulation; hemodynamically significant aortic stenosis; severe peripheral arterial disease; active cerebrovascular event. Relative: Hypertensive urgency (elevated BP without end-organ damage — stabilize first); triple antihypertensive therapy (increased hypotension risk); renal artery stenosis; pheochromocytoma (unpredictable BP response to autonomic stimulation).

Part VII: Comparison with Non-Pharmacological Approaches

Positioning leech therapy among non-pharmacological antihypertensive interventions requires comparison with established approaches. The following data are drawn from meta-analyses and clinical guidelines:

Intervention	SBP Reduction	Evidence Level	Adherence	Sessions
DASH diet	−11 mmHg	Level I (multiple RCTs)	<30% at 12 months	Continuous (lifestyle)
Aerobic exercise	−5–8 mmHg	Level I	~50% at 6 months	3–5×/week (ongoing)
Weight loss (5 kg)	−4–5 mmHg	Level I	<20% sustained at 2 years	Continuous (lifestyle)
Sodium restriction	−5–6 mmHg	Level I	<25% sustained	Continuous (dietary)
Acupuncture	−3–7 mmHg	Level I–II (mixed results)	Moderate	Varies by trial: 22 sessions over 6 weeks (Flachskampf 2007); single session to 60 sessions over 12 weeks across RCTs
Renal denervation	−5–8 mmHg	Level I (RCTs)	N/A (single procedure)	1 (invasive catheter)
Leech therapy	−10–20 mmHg	Level III–IV (no RCTs)	N/A (clinic-based)	3–5 sessions over 2 weeks

Evidence Limitation

Uncontrolled Russian reports describe systolic falls of roughly 28 mmHg after leech application in small series (for example 172 to 144 mmHg in 12 hypertensive patients with coronary artery disease; Isakhanyan, 1991), but these series had no control groups and no RCT exists; the effect size cannot be quantified. The current evidence level (III-IV) is substantially lower than for lifestyle interventions. A pragmatic RCT comparing leech therapy adjunct vs standard care alone in resistant hypertension would be the single most impactful study the ASH could support for this indication.

Key Takeaways

1. The blood-pressure reductions and improvement rates previously cited here derive from uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists.

2. The available evidence for hypertension is limited to uncontrolled Russian-language observational reports; no verifiable controlled trial exists.

3. Four distinct antihypertensive mechanisms act synergistically: controlled bloodletting, SGS vasodilators, microcirculatory improvement, and somatoautonomic reflex via mastoid process dermatomal stimulation.

4. Some Russian-language reports describe a sustained blood-pressure effect after a course of leech therapy, but the duration and any medication-sparing effect are drawn from uncontrolled observations and have not been confirmed in controlled trials.

5. The mastoid process is the primary application site, with neuroanatomical rationale (C2–C3 dermatome, vagal innervation, baroreflex activation). Secondary sites include precordial, hepatic, and sacral zones.

6. This is a Tier C (Investigational) application. No RCTs exist. The available evidence consists of uncontrolled, unverifiable reports and is insufficient for efficacy claims. A pragmatic RCT in resistant hypertension is the highest-priority research need for this indication.

ASH Research Agenda: Hypertension

Pragmatic RCT in resistant hypertension: Leech therapy adjunct to standard triple therapy vs standard triple therapy alone. Primary outcome: 24-hour ambulatory BP at 4 weeks and 3 months. This would provide Level I evidence and potentially transform the clinical positioning of this indication.
Mechanism validation: Pre- and post-treatment measurement of baroreceptor sensitivity, heart rate variability (HRV), and renal sympathetic nerve activity to confirm the somatoautonomic reflex hypothesis.
Duration-of-effect RCT: Repeated ambulatory BP monitoring at 1, 2, 3, and 6 months post-treatment to define the duration profile and optimal retreatment interval.
Dose-response study: Comparison of 3-session vs 5-session vs 8-session courses to define the optimal treatment intensity.
Subgroup analysis registry: Systematic collection of outcomes stratified by hypertension stage, age, etiology (primary vs secondary), and concurrent medications to identify optimal responder populations.

Related Research

Clinical Literature2026

Coagulation factor XI and cardiovascular disease: A complex, cardio-specific conundrum

This review discusses FXI as an emerging anticoagulation target, noting that arterial prevention studies yield conflicting results and that FXI(a) inhibition may work best as add-on therapy. Off-target cardiovascular effects such as blood pressure changes remain inconsistently reported.

Cate et al. · Med (New York, N.Y.)

Clinical Literature2025

Continuous Measurement of Radial Free Forearm Flap Tissue Perfusion for Flap Monitoring After Microvascular Head and Neck Reconstruction-Systemic Blood Pressure as a Potential Confounder in the Early Postoperative Period

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Ooms et al. · Journal of clinical medicine

Clinical Literature2025

Blood pressure and microvascular free flap perfusion in head and neck reconstruction- a retrospective analysis

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Ooms et al. · Oral and maxillofacial surgery

Clinical Literature2021

Chronic Thromboembolic Pulmonary Hypertension Medical Management.

Chronic thromboembolic pulmonary hypertension (CTEPH) is a common long-term complication of pulmonary embolism characterized by thromboembolic obstruction of the pulmonary arteries, vascular arteriopathy, vascular remodeling, and ultimately pulmonary hypertension (PH).

Logue R et al. · Methodist DeBakey cardiovascular journal

Clinical Literature2014

Chronic thromboembolic pulmonary hypertension.

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but debilitating and life-threatening complication of acute pulmonary embolism. CTEPH results from persistent obstruction of pulmonary arteries and progressive vascular remodelling. Not all patients presenting with CTEPH have a history of clinically overt pulmonary embolism.

Hoeper MM et al. · The Lancet. Respiratory medicine

Clinical Literature2012

Pulmonary embolism and deep vein thrombosis.

Pulmonary embolism is the third most common cause of death from cardiovascular disease after heart attack and stroke. Sequelae occurring after venous thromboembolism include chronic thromboembolic pulmonary hypertension and post-thrombotic syndrome. Venous thromboembolism and atherothrombosis share common risk factors and the common pathophysiological characteristics of inflammation, hypercoagulability, and endothelial injury.

Goldhaber et al. · Lancet (London, England)